Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

20206,928 citationsJournal Articlebronze Open Access

Authors

Richard S. Finn · UCLA Jonsson Comprehensive Cancer Center

Shukui Qin · Nanjing General Hospital of Nanjing Military Command

Masafumi Ikeda · National Cancer Center Hospital East

Peter R. Galle · Johannes Gutenberg University Mainz

Michel Ducreux · Université Paris-Saclay

Tae‐You Kim · New Generation University College

Masatoshi Kudo

Abstract

In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT03434379.).

Topics & Keywords

Hepatocellular Carcinoma Treatment and Prognosis Colorectal Cancer Treatments and Studies Cancer Mechanisms and Therapy

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 382, Issue 20, pp. 1894-1905

DOI: 10.1056/nejmoa1915745

Field-Weighted Citation Impact: 509.59